National expert consensus: Definition of diagnostic, therapeutic and follow-up criteria for Cushing's disease in Colombian patients
PDF (Español (España))
HTML (Español (España))


Cushing´s disease
Clinical diagnosis
Pituitary adenoma
Pituitary function tests
Diagnostic imaging
Follow up care

How to Cite

Abreu-Lomba , A. ., Rojas García, W., Guzmán Perlaza, F. ., Tovar Cortés, H. ., Pinzón Tovar, A., Syro Moreno, L. ., Gutiérrez Restrepo, J. ., Román-González, A., Rojas Melo, L. ., & Guerra Rodríguez, N. . (2023). National expert consensus: Definition of diagnostic, therapeutic and follow-up criteria for Cushing’s disease in Colombian patients. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(3).


Background: Cushing's disease is a rare disease in the general population, with an insidious clinical evolution, which creates a for timely diagnosis based on clinical suspicion. Taking into account the origin of the disease given by the presence of a pituitary tumor that secretes adrenocorticotropic hormone (ACTH); treatment should be aimed at achieving biochemical control and resection of the tumor mass. Patient follow-up aimed at monitoring the control of the disease and early detection of the development of comorbidities is a key aspect in the proper management of the disease.

Purpose: To define criteria for the diagnosis, treatment and follow-up of Cushing's disease in Colombian patients.

Methodology: A modified Delphi-type consensus was drawn up with a multidisciplinary group of experts in the management of patients with Cushing's disease (endocrinologists and neurosurgeons) and the consensus was directed by a clinical pharmacologist. The results were analyzed and discussed. Based on the achievement of consensus, a series of recommendations are presented in the different sections of Cushing's disease.

Results: Recommendations based on expert opinion were generated for the approach to the patient with Cushing's disease, including aspects of clinical suspicion; biochemical and imaging diagnosis; treatment by surgical intervention; pharmacological treatment alternatives; radiosurgery and patient follow-up.

Conclusions: In Colombia it is important to strengthen medical knowledge from primary care to specialists with high expertise in issues such as the correct diagnosis, management and follow-up of the patient with Cushing's disease to achieve early detection of the disease and reduce the progression of the diseases. associated comorbidities.
PDF (Español (España))
HTML (Español (España))


Findling J, Raff H. Cushing’s syndrome: Important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91(10):3746-53.

Aron DC. Cushing’s Syndrome from Bedside to Bench and Back: A Historical Perspective. Endocrinol Metab Clin North Am. 2005 jun.;34(2):257-69.

Chaudhry HS, Singh G. Cushing Syndrome. Treasure Island, Florida: StatPearls Publishing; 2023.

Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. The Lancet. 2006 my.;367(9522):1605-17.

Jeong Y, Han H, Lee H, Yang J, Jeong J, Ki Choi M, et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat. 2016;48(4):1429-37.

Hwang J, Weiss R. Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102.

Araya AV, Liberman C, Munizaga C, Pineda P, Barberán M, Cordero F, et al. Combination of High Prevalence Sign/Symptom Pairs: An Approach to the Diagnosis of Cushing’s Syndrome. En: Adrenal Glands - The Current Stage and New Perspectives of Diseases and Treatment [Working Title]. IntechOpen; 2022 [citado 2023, agosto 8]. Disponible en:

Nieman LK. Diagnosis of Cushing’s Syndrome in the Modern Era. Endocrinol Metab Clin North Am. 2018 jun,;47(2):259-73.

Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s Syndrome. Endocrinol Metab Clin North Am. 2008 mzo.;37(1):135-49.

Chabre O. The difficulties of pseudo-Cushing’s syndrome (or “non-neoplastic hypercortisolism”). Ann Endocrinol. 2018 jun.;79(3):138-45.

Santos S, Santos E, Gaztambide S, Salvador J. Diagnóstico y diagnóstico diferencial del síndrome de Cushing. Endocrinol Nutr. 2009 febr.;56(2):71-84.

Pecori Giraldi F. PseudoCushing: why a clinical challenge? J Endocrinol Invest. 2015 oct.;38(10):1137-9.

Zada G. Diagnosis and Multimodality Management of Cushing’s Disease: A Practical Review. Int J Endocrinol. 2013;2013:1-7.

Tritos N, Biller B, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279-89.

Raff H, Sharma S, Nieman L. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing’s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014;4(2):739-69.

Clayton RN. Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality. J Neuroendocrinol. 2022 ag.;34(8).

García Valdés M, Suárez Marín M. El método Delphi para la consulta a expertos en la investigación científica. Rev Cuba Salud Pública. 2013;39(2):253-67.

Joint Commission international. Accreditation standards for Hospitals; 2021.

Matas A. Diseño del formato de escalas tipo Likert: un estado de la cuestión. Rev Electrónica Investig Educ. 2018 febr. 9;20(1):38.

Patrão Neves M. Consensus. En: ten Have H, editor. Encyclopedia of Global Bioethics. Cham: Springer International Publishing; 2015 [citado 14 de abril de 2023]. p. 1-9. Disponible en:

Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM Levels of Evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine. [Internet]. Disponible en:

Castinetti F, Morange I, Conte-Devolx B, Brue T. Cushing’s disease. Orphanet J Rare Dis. 2012;7(1):41.

Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 ag.;100(8):2807-31.

Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021 dic.;9(12):847-75.

Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al. Time to Diagnosis in Cushing’s Syndrome: A Meta-Analysis Based on 5367 Patients. J Clin Endocrinol Metab. 2020 mzo. 1;105(3):e12-22.

Pinzon-Tovar A, Oviedo-Cali M, Jimenez-Salazar S, Mendez H, Buitrago-Toro K. Hipercortisolismo severo e hipocalemia recurrente. Acta Méd Perú. 2022 ag.;39(2).

Gutiérrez-Restrepo J, Román-González A. Síndrome de Cushing ectópico: revisión de la literatura. Rev Colomb Cancerol. 2016 oct.;20(4):175-82.

Syro L, Rotondo F, Kovacs K, Korbonits M. Clinicopathologic features of familial pituitary adenomas. Diagn Histopathol. 2016;22(3):85-91.

García Botina HD, Lara Botina DR, Mauricio Sánchez F, Román González A. Presentación de tres casos y revisión en la literatura: Síndrome de Cushing. Arch Med Manizales. 2017 dic. 6;17(2):415-24.

Santos S, Santos E, Gaztambide S, Salvador J. Diagnóstico y diagnóstico diferencial del síndrome de Cushing. Endocrinol Nutr. 2009 febr.;56(2):71-84.

Galm BP, Qiao N, Klibanski A, Biller BM, Tritos NA. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2020 jun. 1;105(6):2081-94.

Savas M, Mehta S, Agrawal N, van Rossum EF, Feelders RA. Approach to the Patient: Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2022 nov. 23;107(11):3162-74.

Espinosa de los Monteros-Sánchez A. Consenso en el diagnóstico y tratamiento del síndrome de Cushing. Rev Endocrinol Nutr. 2007;15(4):S3-12.

Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing’s Disease. Clin Med Insights Oncol. 2012 en.;6:CMO.S6198.

Honegger J, Nasi?Kordhishti I. Surgery and perioperative management of patients with Cushing’s disease. J Neuroendocrinol. 2022 ag.;34(8).

Araujo-Castro M, Pascual-Corrales E, Martínez San Millan JS, Rebolleda G, Pian H, Ruz-Caracuel I, et al. Postoperative management of patients with pituitary tumors submitted to pituitary surgery. Experience of a Spanish Pituitary Tumor Center of Excellence. Endocrine. 2020 jul.;69(1):5-17.

Feelders RA, Hofland LJ. Medical Treatment of Cushing’s Disease. J Clin Endocrinol Metab. 2013 febr.;98(2):425-38.

Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, et al. Medical Treatment of Cushing’s Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol. 2020 dic. 8;11:648.

Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol. 2019 abr.;7(4):300-12.

Hughes JD, Young WF, Chang AY, Link MJ, Garces YI, Laack N, et al. 209 Radiosurgical Management of Patients With Persistent or Recurrent Cushing’s Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience. Neurosurgery. 2018 sept. 1;65(supl. 1):118.

Pence A, McGrath M, Lee SL, Raines DE. Pharmacological management of severe Cushing’s syndrome: the role of etomidate. Ther Adv Endocrinol Metab. 2022 en.;13:204201882110585.

Santos A, Resmini E, Martínez Momblán MA, Valassi E, Martel L, Webb SM. Quality of Life in Patients With Cushing’s Disease. Front Endocrinol. 2019 dic. 11;10:862.

Serban AL, Del Sindaco G, Sala E, Carosi G, Indirli R, Rodari G, et al. Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. J Endocrinol Invest. 2020 my.;43(5):631-9.

Le Marc’hadour P, Muller M, Albarel F, Coulon AL, Morange I, Martinie M, et al. Postoperative follow-up of Cushing’s disease using cortisol, desmopressin and coupled dexamethasone-desmopressin tests: a head-to-head comparison. Clin Endocrinol (Oxf). 2015 ag.;83(2):216-22.

Guignat L, Bertherat J. Long?term follow?up and predictors of recurrence of Cushing’s disease. J Neuroendocrinol. 2022 ag.;34(8).

Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing’s disease. Pituitary. 2015 abr.;18(2):188-94.

Schernthaner-Reiter MH, Siess C, Gessl A, Scheuba C, Wolfsberger S, Riss P, et al. Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission. Endocrine. 2019 abr.;64(1):157-68.

Ferraù F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol. 2015 oct.;173(4):M133-57.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.